What Does the Published Research Say About Follistatin-344?

What This Article Covers

This article summarizes published research on Follistatin-344 for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

Follistatin is a secreted protein that binds and neutralizes activins and related TGF-β family ligands. “Follistatin-344” (FST344) refers to a 344–amino-acid isoform; however, most sources in this evidence set discuss follistatin generally (and sometimes follistatin-like 3, FSTL3), not isoform-specific clinical outcomes for FST344 [pubmed:9785474; pubmed:15253386; pubmed:37739334]. The evidence set contains:

• Human studies in disease-specific, non-interventional contexts (FLT3/ITD acute myeloid leukemia target/biomarker work; circulating hormone profiling in steatotic liver disease; serum follistatin levels in ovarian endometriosis) [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1].
• Multiple reviews on activin/follistatin biology and related systems [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318].
• Preclinical/mechanistic reports (cancer cachexia pathway mapping; angiogenin-binding) [pubmed:39116208; pubmed:17991437].
• A nonclinical PK/PD study of an engineered human follistatin variant (not FST344) [crossref:10.1124/jpet.112.0313hia].
• Forensic/analytical detection of black-market FST344 [pubmed:31758732; crossref:10.1002/dta.2741; crossref:10.1002/dta.2882].

Isoform specificity clarification: the evidence set does not present isoform-specific clinical data for FST344; conclusions should not assume equivalence between total follistatin, FST344, and FSTL3.

Bottom Line

In this evidence set, direct human evidence related to follistatin is narrow and disease-specific, focusing on target/biomarker work in FLT3/ITD acute myeloid leukemia, circulating hormone measurements in biopsy-proven steatotic liver disease, and serum levels in ovarian endometriosis cohorts [pubmed:32134197; pubmed:37757973; crossref:10.1016/s1090-798x(10)79409-1]. None of the cited human studies involve interventional administration of exogenous FST344. Mechanistic reviews describe how follistatin modulates activin/TGF-β pathways, providing context but not clinical outcomes [pubmed:9785474; pubmed:10077456; pubmed:37739334; pubmed:15253386; pubmed:31322318]. Preclinical reports map disease-relevant pathways and protein–protein interactions, and analytical studies document detection of black-market FST344; these do not establish clinical efficacy, safety, or dosing for FST344 [pubmed:39116208; pubmed:17991437; crossref:10.1124/jpet.112.0313hia; pubmed:31758732]. Overall, any conclusions should remain anchored to the specific human populations and endpoints studied and should not be generalized.

What Was Tested in Humans?

No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for Follistatin-344 is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for Follistatin-344 is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• [pubmed:32134197]
• [pubmed:37757973]
• [crossref:10.1016/s1090-798x(10)79409-1]
• [pubmed:9785474]
• [pubmed:10077456]
• [pubmed:37739334]
• [pubmed:15253386]
• [pubmed:31322318]
• [pubmed:15451564]
• [pubmed:39116208]
• [pubmed:17991437]
• [crossref:10.1124/jpet.112.0313hia]
• [pubmed:31758732]
• [crossref:10.1002/dta.2741]
• [crossref:10.1002/dta.2882]

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ